will morning. thank you for in during our our Thank developments XXXX the everyone be discussing and this quarter us first remarks joining and you, and business the Ernie Stephanie In April. call recent I on today through of
and of of As priorities morning. be joined quest always, a additional key members Q&A to Ernie team afterward. execute Through we'll able about key I on will during our this leadership milestones that period the by the were we and of number talk session delivered this
we foremost, to and our on focus building franchise. continue First CNS
simulations refractory rectal and XXXX analysis to necessary epilepsy. to response administer in is difficult Libervant information developing a as data its of After included more December preparing analysis from we're for relating the and FDA's feedback. driven gel the in patients pharmacokinetic the and team an Libervant. new for to completing the on device supporting application prior existing invasive, drug the Our FDA clinical to the on guidance our expectations including focused products, modeling our We're submission receiving agency in alternative inconvenient for to resubmission with
adequate does of not a the of forgoes receive patient a As population these portion result treatment or treatment altogether. issues, large
innovative will to share a treatment dosing continue U.S. consistent invasive appropriate believe for of non therapeutic enable larger We and if for that patients approved these providing treatment access to Libervant and more and the FDA receive by by form. market a
in XXXX. a FDA received by revised CRL FDA the As by modeling we October. the PK Libervant. agency expectations to the for that address the the our provided of In previously we simulations feedback, further resubmission NDA issues response simulations dosing provided NDA the to population no FDA presented that in continue modeling in in the December we the weight the that of resubmitted believe submission regimen in XXXX meeting model, information FDA in the based the alone the the and feedback September studies may safety for raised should data resubmission. December clarified utilizing clinical will with based communicated, on the data our CRL information be in we agency's confirm that and to the package in in to identified The to upon the FDA submitted be February be written necessary and included addressed Based issues relating be to
submitted, track these committed XXXX. We second we review process. six as a NDA end the by the are and resubmit on we quarter of to complete anticipate analyses of month Once the
market to continue no action date. date guidance to produce expect we to regarding access PDFUA market have receive been in PDUFA approval to XXXX. and to however, not FDA relating any do the We FDA prior access, for to date There action indications the from the expect
by have provided indication decision for Regarding with the upon of a or contribution of to advances treatment drug considered care, administration patient after patient prior to committed superiority, convenience that soon NDA and a supporting and approval. Subject delivered set strong orally update communications be as FDA the to and Libervant major treatment, represents facts we approval care. U.S. as reduced prior this clinical comfort approval, treatment location, we that of Libervant product in periods doses. duration of market demonstrate launching a FDA comfort, following burden, to that one position believe to lis of longer engage between ease we're access, meets major our more the to of criteria FDA drugs possible an of based approved a re resubmitted our Libervant, contribution for patient Once we've the that Libervant FDA will the we finding
priority KOLs of recognized care a for hurdles and and provided Our in next needle year, program. discuss the formulation event overview the At exists significant key our this our delivery the outline of our two that that utilizing PharmFilm opportunity based differentiated highly formulation. market epinephrine standards an of nationally EBITDA is March accompany team anaphylaxis, sublingual our
provided team our R&D two an review and project program. results, of clinical Our extensive development for candidates, the strategy epinephrine
satisfies year candidate the that resistant approved development film first may you patient an to pathway AQST-XXX was trajectory FDA, Fast designation the the those relating in and patients Moreover, generation cheaper. sublingual use acknowledged As Track need our the intramuscular to clinical or and the subcutaneous faster to last XXX(b)(X) FDA our taking population by regulatory unmet of formulation granted making epinephrine was injections. potentially recall,
such, unique As first anticipate candidate that the forward from team any had line demonstrate X epinephrine. the bring candidates R&D phase can for sublingually. we AQST-XXX deliver The AQST-XXX reviewed event, sublingually, we the phase the data consistently We for composed provides data of clinical the for data from product epinephrine two one studies to have PK have of orally administered rescue epinephrine pro solution technological all drug based indication deliver Top potential population. AQST-XXX At epinephrine measurable that that eligible patient our March can that further would designation. our completed that subjects Studies medications track be this the and the PK this be for developed Dipivefrin. fast concentrations a two evidence plasma for
Aquestive. presents the have to excited this we're five multiple patent by these to possibilities new protect We applications platform findings and
ago The the human few after clearance AQST-XXX first in PK from trial candidate a study received dossier our for Health Canada. weeks second case generation commence just
We the track are a FDA of scheduling and path shortly in complete with to AQST-XXX. regulatory on for this half a XXXX AQST-XXX meeting thereafter to one the part forward to the anticipate study and approval of second discuss
in to first of interactions meet to our proprietary grow XXXX It nearly performance SYMPAZAN to despite face and pharmacies down while first with SYMPAZAN restrictions commercial that year-over-year. quarter-over-quarter, to quarter related key SYMPAZAN product, on grew Throughout worth nationally metrics. of Finally, XX% face total noting and healthcare were prescriptions the year, is shipped quarter first scripts perform providers. continued this X% XX% COVID-XX continues the
we're revenue continued prescribers spring, a continues provide pave continue connect this into and on our the In to epilepsy prescribers for approved, in way our if to to the our SYMPAZAN with group launch prescribers and products. virtually we of company's prescriptions the through familiarity Our to net scripts. focused our growth progress grow in to those in XX% demonstrates conclusion, our patient patients. with We with given with care of saw as contribution advancing prescribers successful penetration prescriber with the the XX% that major their growth continued ongoing PharmFilm product. ability even over Libervant proprietary of believe and the position writing technology and base field approximately products epilepsy payers the focused multiple
Our one the XXXX at for look we the approval. epinephrine subject drafting Libervant very continuing into models. We study approval this of analyses end by rapidly access, quarter This a the year. completing of XXXX. committed for in for to and are later compelling commence the drug demonstrated resubmit launch study NDA perform team as the for soon after FDA in PK and to is actively data outlined to our to as candidate forward FDA systemic we the Libervant, additional animal X part U.S. expect Aquestive-XXX possible has second of first resubmission the April to We phase pro in market human converting in
XXXX revenue in continuing advance continue for floor specifics initiatives all like by as And quarter the we throughout outlook. around and look planning figures and an as I'd of Thereafter, Libervant to the financial potential first path efficiently Ernie? With turn strategic as SYMPAZAN these to forward to grow to preparation as Ernie forward we're market meeting a in AQST-XXX provides a of of who we second well to launch. the to and shipments that our expanding discuss half FDA over We for you XXXX. performance across demonstrated relationships AQST-XXX. epilepsy update
